Systemische Therapie der moderaten bis schweren Psoriasis vulgaris mit Biologika

Zusammenfassung

Die Psoriasis vulgaris ist eine eigenständige Erkrankung mit einem signifikanten Leidensdruck für das betroffene Individuum und einer enormen sozioökonomischen Bedeutung. In den vergangenen Dekaden führten tiefere Einblicke in diese Erkrankung zur Entwicklung von Biologika, die diverse spezifische Zytokine angreifen. Diese Übersichtsarbeit fasst kurz relevante pathophysiologische Aspekte zusammen und fokussiert anschließend auf die systemische Therapie mit Biologika. Im letzten Abschnitt werden neue, sich bereits in klinischer Erprobung befindende Therapieoptionen perspektivisch angerissen.

Summary

Psoriasis vulgaris is a distinct disease with a significant disease burden for the affected individual and an enormous socio-economic impact. In the last decades the deeper insight into this disease led to the development of biologics targeting several specific cytokines. This review shortly summarizes pathophysiological aspects and subsequently focuses on the systemic therapy with biological agents. In the last step new treatment options that are being currently investigated in clinical trials will be highlighted.

Schlüsselwörter

Psoriasis vulgaris - Biologika - Infliximab - Adalimumab - Etanercept - Ustekinumab

Keywords

Psoriasis vulgaris - biologics - infliximab - adalimumab - etanercept - ustekinumab

• Literatur

• 1 Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352 (18) 1899-1912.
• 2 Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4 (07) 441-447.
• 3 Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361 (05) 496-509.
• 4 Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26 (04) 314-320.
• 5 Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370 (9583) 272-284.
• 6 Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141 (02) 185-191.
• 7 Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol 2007; 123 (02) 129-138.
• 8 Gottlieb AB, Evans R, Li S. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51 (04) 534-542.
• 9 Chaudhari U, Romano P, Mulcahy LD. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357 (9271) 1842-1847.
• 10 Reich K, Nestle FO, Papp K. et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366 (9494) 1367-1374.
• 11 Menter A, Feldman SR, Weinstein GD. et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56 (01) 31 e31-e15.
• 12 Barker J, Hoffmann M, Wozel G. et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165 (05) 1109-1117.
• 13 Smith CH, Anstey AV, Barker JN. et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153 (03) 486-497.
• 14 Saurat JH, Stingl G, Dubertret L. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158 (03) 558-566.
• 15 Strober BE, Poulin Y, Kerdel FA. et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 64 (04) 671-681.
• 16 Thaci D, Ortonne JP, Chimenti S. et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163 (02) 402-411.
• 17 Van den Bosch F, Manger B, Goupille P. et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69 (02) 394-399.
• 18 Saraceno R, Bianchi L, Pietroleonardo L. et al. Remission and time of resolution of nail psoriasis: a comparison among antitumor necrosis factor-inhibitors. Br J Dermatol 2008; 159 (06) 1418.
• 19 Viguier M, Pages C, Aubin F. et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 2012; 167 (02) 417-423.
• 20 Burmester GR, Mariette X, Montecucco C. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66 (06) 732-739.
• 21 Tyring S, Gottlieb A, Papp K. et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367 (9504) 29-35.
• 22 Leonardi CL, Powers JL, Matheson RT. et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349 (21) 2014-2022.
• 23 Mease PJ, Goffe BS, Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356 (9227) 385-390.
• 24 Gottlieb AB, Matheson RT, Lowe N. et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139 (12) 1627-1632 discussion 1632.
• 25 Papp KA, Tyring S, Lahfa M. et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152 (06) 1304-1312.
• 26 Paller AS, Siegfried EC, Langley RG. et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358 (03) 241-251.
• 27 Tyring S, Gordon KB, Poulin Y. et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143 (06) 719-726.
• 28 Paller AS, Siegfried EC, Eichenfield LF. et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63 (05) 762-768.
• 29 Luger TA, Barker J, Lambert J. et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23 (08) 896-904.
• 30 Leonardi CL, Kimball AB, Papp KA. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625) 1665-1674.
• 31 Krueger GG, Langley RG, Leonardi C. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (06) 580-592.
• 32 Papp KA, Langley RG, Lebwohl M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625) 1675-1684.
• 33 Griffiths CE, Strober BE, van de Kerkhof P. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362 (02) 118-128.
• 34 Clemmensen A, Spon M, Skov L. et al. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25 (09) 1037-1040.
• 35 Rigopoulos D, Gregoriou S, Makris M, Ioannides D. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011; 223 (04) 325-329.
• 36 Lebwohl M, Leonardi C, Griffiths CE. et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66 (05) 731-741.
• 37 Gordon KB, Papp KA, Langley RG. et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66 (05) 742-751.
• 38 Kimball AB, Gordon KB, Fakharzadeh S. et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166 (04) 861-872.
• 39 Martin DA, Towne JE, Kricorian G. et al. The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. J Invest Dermatol. 2012 Jun 7. doi:
• 40 Papp KA, Reid C, Foley P. et al. Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial. J Invest Dermatol. 2012 May 24.
• 41 Leonardi C, Matheson R, Zachariae C. et al. Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366 (13) 1190-1199.
• 42 Hueber W, Patel DD, Dryja T. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2 (52) 52ra72.
• 43 Papp KA, Leonardi C, Menter A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366 (13) 1181-1189.